Coroflo, an Ireland-based medtech startup, has secured €2.8 million in equity funding to launch its breastfeeding monitor, named Coro. This latest round of funding brings the total equity investment in the company to €4.2 million. The Coro device, featuring a patented micro-flow meter within a standard silicone nipple shield, aims to provide real-time data on milk flow to nursing mothers, addressing concerns over milk supply.
Coroflo, founded in 2017 by CTO Jamie Travers and Chief Research Officer Dr. Helen Barry, is led by CEO Rosanne Longmore. The company is headquartered in Dublin and is preparing for the commercial launch of its Coro breastfeeding monitor. The funding round attracted contributions from Brian Caulfield of Scale Ireland, Shemas Eivers of the Boole Syndicate, and several private investors who had previously supported Coroflo’s seed round. The company plans to use the funds to double its workforce and move to larger offices at the DCU Alpha campus, with the product expected to hit the market in the second half of 2024.
Coroflo has established commercial contracts with Irish pharmacy chains McCabe and McCauley’s, indicating a pathway to market availability for Coro. Additionally, the company has received a €2.1 million accelerator grant from the European Commission under its Horizon 2020 program, which supported independent clinical research at a Dublin maternity hospital. Coroflo’s development has also been supported by Enterprise Ireland through its High Potential Start-Up program.
Rosanne Longmore, CEO of Coroflo, shared with The Irish Times: “Coro is groundbreaking, in terms of its core technology and how it will help mothers achieve their own breastfeeding goals. Any positive increase in breastfeeding rates has a hugely significant knock on effect on the wider health population outcomes for society as a whole. As we move out of the R&D phase and into manufacturing, launch and commercialization, we are excited to have the backing of new investors and existing long standing investors. This latest funding round evidences our investors’ confidence in both the technical and management team and will allow Coro to be made available to mothers for the first time.”
